EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Alpelisib decreases nevocytes of congenital melanocytic nevi

Alejandra Tomás-Velázquez iD, Juan Carlos López-Gutiérrez, Carlos de Andrea, Miguel Reyes-Múgica, Claudia M Salgado, Pedro Redondo iD

Journal of the European Academy of Dermatology and Venereology · 2024

DOI: 10.1111/jdv.19736 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von Alejandra Tomás-Velázquez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Clinic of Navarra, Madrid, Spain. Hauptthemen laut MEDLINE: Nevus, Pigmented, Skin Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Multiple, large or giant congenital melanocytic nevi (CMN) are uncommon and affected patients can show progressive growth and thickening, associate neurocutaneous melanocytosis or develop melanoma. Current treatment modalities are mostly complex surgeries that frequently do not solve the disease and its risks completely. Thus, investigation on new treatment options for CMN and its complications must continue. MAPK pathway inhibitors are being investigated, also targeting PI3K‐AKT. Omipalisib (PI3K inhibitor, with no indications approved yet) has been studied for CMN in vitro and in mice with promising results. However, alpelisib, a PI3K inhibitor approved with an adequate safety profile for patients with severe manifestations of PROS (PIK3CA‐Related Overgrowth Spectrum), had not yet been tested for CMN.

Objective

To evaluate the effect of alpelisib in nevocytes of congenital melanocytic nevi.

Methods

Nevomelanocytic tissue samples of 10 patients were collected prospectively and, following a previously reported preclinical ex vivo model, explants were placed in organotypic culture for 5 days, with or without alpelisib. Consecutively, tissue sections were stained and using scanned images with Qupath and ImageJ softwares, representative regions from the dermis were analysed (using Wilcoxon test and Spearman's correlation).

Results

When comparing alpelisib‐treated explants with respect to control explants, we found a decrease in cell density ( p = 0.0273), in density of SOX10 + ‐cells ( p = 0.0391) and also in the % of S‐100 + area ( p = 0.0078), in alpelisib samples. The three markers showed a positive correlation ( p < 0.05).

Conclusions

This study provides first‐time evidence that alpelisib induces nevocyte reduction in CMN from patient‐derived explants, probably inducted by autophagy. Alpelisib is an approved drug with an adequate safety profile used in another mosaicism affecting PI3K (PROS). Further studies are needed to evaluate its efficacy in treating CMN and potentially, their complications, either with local or systemic administration, alone or in combination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nevus, PigmentedSkin NeoplasmsHumansFemaleMaleChildChild, PreschoolAdolescentProspective StudiesInfantMelanocytesThiazoles

Substanzen

AlpelisibThiazoles

Autor:innen und Institutionen

  • Department of Dermatology, University Clinic of Navarra, Madrid, Spain.
  • Department of Pediatric Surgery, Hospital La Paz, Madrid, Spain.
  • Department of Pathology, University Clinic of Navarra, Pamplona, Spain.
  • Department of Pathology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Alejandra Tomás-Velázquez, Pedro Redondo

Förderung

  • Instituto de Salud Carlos III

Zitieren

APA

Tomás-Velázquez, A., López-Gutiérrez, J. C., de Andrea, C., Reyes-Múgica, M., Salgado, C. M., & Redondo, P. (2024). Alpelisib decreases nevocytes of congenital melanocytic nevi. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19736

Vancouver

Tomás-Velázquez A, López-Gutiérrez JC, de Andrea C, Reyes-Múgica M, Salgado CM, Redondo P. Alpelisib decreases nevocytes of congenital melanocytic nevi. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19736

BibTeX
@article{TomsVelzquez2024,
  author = {Tomás-Velázquez, Alejandra and López-Gutiérrez, Juan Carlos and de Andrea, Carlos and Reyes-Múgica, Miguel and Salgado, Claudia M and Redondo, Pedro},
  title = {Alpelisib decreases nevocytes of congenital melanocytic nevi},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2024},
  doi = {10.1111/jdv.19736}
}
Kostenlos starten →